What is the official website of Intas Pharmaceuticals ?

The official website of Intas Pharmaceuticals is https://intaspharma.com.

What is Intas Pharmaceuticals's cybersecurity risk score?

Intas Pharmaceuticals has an AI-generated cybersecurity risk score of 795 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Intas Pharmaceuticals experienced?

According to Rankiteo, Intas Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Intas Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Intas Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Intas Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Intas Pharmaceuticals is not certified under SOC 2 Type 1.

Does Intas Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Intas Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Intas Pharmaceuticals comply with GDPR ?

According to Rankiteo, Intas Pharmaceuticals is not listed as GDPR compliant.

Does Intas Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Intas Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Intas Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Intas Pharmaceuticals is not compliant with HIPAA regulations.

Does Intas Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Intas Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Intas Pharmaceuticals operate in ?

Intas Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Intas Pharmaceuticals have ?

Intas Pharmaceuticals employs approximately 18,773 people worldwide.

Does Intas Pharmaceuticals own any subsidiaries ?

Intas Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Intas Pharmaceuticals have ?

Intas Pharmaceuticals's official LinkedIn profile has approximately 855,228 followers.

What is the NAICS classification code for Intas Pharmaceuticals ?

Intas Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Intas Pharmaceuticals have a Crunchbase profile ?

No, Intas Pharmaceuticals does not have a profile on Crunchbase.

Does Intas Pharmaceuticals have a LinkedIn profile ?

Yes, Intas Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/intas-pharmaceuticals.

How many cybersecurity incidents has Intas Pharmaceuticals experienced ?

As of August 19, 2026, Rankiteo reports that Intas Pharmaceuticals has not experienced any cybersecurity incidents.

How many peer or competitor companies does Intas Pharmaceuticals have ?

Intas Pharmaceuticals has an estimated 5,728 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Intas Pharmaceuticals

Boost Score +25 with badge (5 left)

795

/1000

Fair

820

/1000

Good

Intas Pharmaceuticals Vendor Cyber Rating & Cyber Score

intaspharma.com

Add Your Compliance Badge

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India.

Intas Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Intas Pharmaceuticals

Intas Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Intas Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Intas Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intas Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Intas Pharmaceuticals in 2026.

Incident Types Intas Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intas Pharmaceuticals in 2026.

Incident History - Intas Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Intas Pharmaceuticals Subsidiaries

Intas Pharmaceuticals

Pharmaceutical Manufacturing

Website: https://intaspharma.com

Company Size: 10,000+ employees

Intas B2BPharmaceutical Manufacturing

Loading…

Intas Pharmaceuticals Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Loading…

NEWS

Intas Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 18, 2025 08:00 AM

Intas Pharmaceuticals Appoints Dr. Pramod Kharwade as VP- Formulation & Development

Intas Pharmaceuticals has announced the appointment of Dr. Pramod Kharwade as the Vice President of Formulation and Development.

Read Article

December 20, 2022 08:00 AM

Sumeet Khokhani joins Reliance Industries as VP Cybersecurity

Cybersecurity expert Sumeet Khokhani has joined Reliance Industries as Vice President - IRM & Cybersecurity. Before joining Reliance...

Read Article

September 06, 2010 07:00 AM

Intas Pharma plans Rs.800 Crore IPO to fund acquisitions

Intas Pharmaceuticals, an Ahmedabad-based company, is planning for a public issue of 750-800 crore with an objective to raise fresh funds for acquisitions.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-66591

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in David Lingren Media LIbrary Assistant allows Stored XSS. This issue affects Media LIbrary Assistant: from n/a through 3.39.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

2.3

REFERENCES

https://patchstack.com/database/wordpress/plugin/media-library-assistant/vulnerability/wordpress-media-library-assistant-plugin-3-39-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-66589

SUMMARY

Missing Authorization vulnerability in Kings Plugins B2BKing allows Exploiting Incorrectly Configured Access Control Security Levels. This issue affects B2BKing: from n/a through 5.2.30.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://patchstack.com/database/wordpress/plugin/b2bking-wholesale-for-woocommerce/vulnerability/wordpress-b2bking-plugin-5-2-30-broken-access-control-vulnerability?_s_id=cve

CVE-2026-27365

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in PublishPress PublishPress Series allows Stored XSS. This issue affects PublishPress Series: from n/a through 2.17.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

1.7

REFERENCES

https://patchstack.com/database/wordpress/plugin/organize-series/vulnerability/wordpress-publishpress-series-plugin-2-17-0-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-73974

SUMMARY

linuxfabrik-lib provides Python modules for database access, caching, shell execution, and API integrations, and Linuxfabrik Monitoring Plugins uses its shared testing helper across check plugins. Prior to linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0, lib.lftest.test() treated the first or second element of a --test CSV argument as a filesystem path and returned the file contents as simulated standard output or standard error without path confinement. The hidden but production-accessible --test argument was accepted by sudo-authorized plugins, so an attacker controlling the nagios or icinga account could use check-plugins/deb-updates/deb-updates with its default QUERY=1 to disclose every line of a root-readable file. Approximately 22 other plugins exposed filtered content or a root file existence and readability oracle through the same helper, while check-plugins/network-bonding/network-bonding and check-plugins/openstack-swift-stat/openstack-swift-stat had direct read paths that bypassed the helper. The library fix confines fixture reads to the invoking plugin's unit-test directory and refuses unsafe anchors, and the plugin fix routes the two bypasses through that helper. These issues are fixed in linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-73973

SUMMARY

Linuxfabrik Monitoring Plugins provides monitoring plugins for Icinga, Nagios, and related systems. Prior to version 7.0.0, check-plugins/logfile/logfile accepted a free-form --filename path and opened it as root when invoked through the shipped nagios or icinga sudoers allowlist, without confining the resolved path to /var/log. An attacker who controls the monitoring account can select a root-readable file such as /etc/shadow and use --warning-regex . while leaving SUPPRESS_OUTPUT false, causing each nonempty line to be collected in warn_matches and returned through lib.base.oao(). The vulnerable flow passes the expanded scan_path directly to open(), and neither real-path containment nor an allowlist protects the sink. The same fix also confines mysql-logfile and openvpn-client-list paths, allows only documented log roots, and resolves symlinks and parent-directory traversal before checking containment. This issue is fixed in version 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…